Ophthalmic Drugs Market by Drug Class (Anti-inflammatory Drugs (Non Steroidal Anti-Inflammatory Drugs and Steroids), Anti-Infective Drugs (Anti-Fungal Drugs, Anti-Bacterial Drugs, Anti-Viral Drugs, and Others), Anti-Glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, and Others), Anti-Allergic Drugs, and Others), by Type (Prescription Drugs and Over-the-Counter Drugs), by Disease Indication (Dry Eye, Allergies, Glaucoma, Retinal Disorders, Inflammation/ Infection, Uveitis, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, and Others)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020 - 2029

                                          
Abstract
                    
The report covers forecast and analysis for the ophthalmic drugs market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the ophthalmic drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the ophthalmic drugs market on a global level.

In order to give the users of this report a comprehensive view of the ophthalmic drugs market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug class, type, disease indication, distribution channel, and regional segments are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on the global and regional basis. 

The study provides a decisive view of the ophthalmic drugs market by segmenting the market based on drug class, type, disease indication, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further divided into major countries.

Some of the leading players in ophthalmic drugs market include Allergan Plc, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Novartis AG, Bayer AG, F.Hoffmann-La Roche Ltd., Santen Pharmaceutical Co., Ltd., Kyowa Hakka Kirin Co., Ltd., Valent Pharmaceuticals International, Inc., Johnson and Johnson Vision Care, Inc. and Shire Plc.

This report segments the global ophthalmic drugs market as follows:

Global Ophthalmic Drugs Market: Drug Class Segment Analysis

	Anti-Inflammatory Drugs
	
		Non-Steroidal Anti-Inflammatory Drugs
		Steroids 
	
	
	Anti-Infective Drugs
	
		Anti-Fungal Drugs
		Anti-Bacterial Drugs
		Anti-Viral Drugs
		Others
	
	
	Anti-Glaucoma Drugs
	
		Alpha Agonist
		Beta Blockers
		Prostaglandin Analogs
		Combined Medication
		Others 
	
	
	Anti-Allergic Drugs
	Others

Global Ophthalmic Drugs Market: Type Segment Analysis

	Prescription Drugs
	Over-the-Counter Drugs

Global Ophthalmic Drugs Market: Disease Indication Segment Analysis

	Dry Eye
	Allergies
	Glaucoma
	Retinal Disorders
	Inflammation/ Infection
	Uveitis
	Others

Global Ophthalmic Drugs Market: Distribution Channel Segment Analysis

	Hospital Pharmacies
	Retail Pharmacies
	Online Sales
	Others

Global Ophthalmic Drugs Market: Regional Segment Analysis

	North America
	
		The U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	The Middle East and Africa